Sustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery.

[1]  Zhaoliang Zhang,et al.  In situ injectable nano-composite hydrogel composed of curcumin, N,O-carboxymethyl chitosan and oxidized alginate for wound healing application. , 2012, International journal of pharmaceutics.

[2]  Yuhua Weng,et al.  A covalently crosslinked polysaccharide hydrogel for potential applications in drug delivery and tissue engineering , 2012, Journal of Materials Science: Materials in Medicine.

[3]  E. Alsberg,et al.  The effect of oxidation on the degradation of photocrosslinkable alginate hydrogels. , 2012, Biomaterials.

[4]  Lin Yu,et al.  In vitro degradation and protein release of transparent and opaque physical hydrogels of block copolymers at body temperature , 2012, Macromolecular Research.

[5]  G. Hsiue,et al.  Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. , 2012, Biomacromolecules.

[6]  Y. Tabata,et al.  Ocular drug delivery for bioactive proteins , 2011 .

[7]  S. Young,et al.  Drug delivery to the posterior segment of the eye. , 2011, Drug discovery today.

[8]  U. Kompella,et al.  Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[9]  Yuquan Wei,et al.  A novel composite hydrogel based on chitosan and inorganic phosphate for local drug delivery of camptothecin nanocolloids. , 2011, Journal of pharmaceutical sciences.

[10]  Shaoyu Lü,et al.  An injectable oxidized carboxymethylcellulose/N-succinyl-chitosan hydrogel system for protein delivery , 2010 .

[11]  Miqin Zhang,et al.  Chitosan-based hydrogels for controlled, localized drug delivery. , 2010, Advanced drug delivery reviews.

[12]  T. Lai,et al.  INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA , 2009, Retina.

[13]  A. Rouvas,et al.  SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMAB: Our Experience After 2,000 Injections , 2009, Retina.

[14]  Bing Kan,et al.  Synthesis and characterization of PEG-PCL-PEG thermosensitive hydrogel. , 2009, International journal of pharmaceutics.

[15]  Ashim K. Mitra,et al.  Recent Perspectives in Ocular Drug Delivery , 2009, Pharmaceutical Research.

[16]  Lihui Weng,et al.  Non-cytotoxic, in situ gelable hydrogels composed of N-carboxyethyl chitosan and oxidized dextran. , 2008, Biomaterials.

[17]  C. Regillo,et al.  INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB , 2008, Retina.

[18]  Joan W. Miller,et al.  Anti-vascular endothelial growth factor therapy for ocular neovascular disease , 2007, Current opinion in ophthalmology.

[19]  L. Yu,et al.  Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[20]  P. Kaiser.  Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. , 2006, American journal of ophthalmology.

[21]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[22]  M. Alonso,et al.  The potential of chitosan in ocular drug delivery , 2003, The Journal of pharmacy and pharmacology.

[23]  H. Park,et al.  Chemical characteristics of O-carboxymethyl chitosans related to the preparation conditions , 2003 .